Skyworks Aeronautics Announces the Order of 100 eGyro™ Electric Aircraft with Options for an Additional 100 by a Consortium of Mint Air and Mobius.energy
24.6.2021 15:15:00 EEST | Business Wire | Press release
Today, Skyworks Aeronautics (“Skyworks”) announces the order of 100 eGyro™ electrically powered vertical take-off and landing (eVTOL) aircraft from a consortium of Mint Air (“Mint”) and Mobius.energy Corp (“Mobius”) with options for an additional 100 aircraft.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210624005323/en/
Notional depiction of the Skyworks eGyro™ (Photo: Business Wire)
“A consortium led by Mint Air is committed to bringing safe, efficient, and cost-effective electric aircraft solutions to South Korea and we are absolutely thrilled they have selected our eGyro as their aircraft of choice to initiate operation of the leading eVTOL service in Korea. We look forward to performing our first public demonstrations of the eGyro in Korea and to launching the eGyro Urban Air Mobility (UAM) platform in the Korean market,” said John Michel, Co-Founder & Executive Director of Skyworks.
“We are pleased to announce the Skyworks eGyro as the launch UAM platform for Mint Air. The fundamental safety and performance advantages of the eGyro will enable Mint Air to accelerate the adoption of intra and inter-city passenger transport in Korea,” said Eugene Choi, Chief Executive Officer of Mint Air.
The consortium led by Mint Air and Skyworks signed a Letter of Intent (LOI) for exclusive partnership in South Korea. The consortium will collaborate with Skyworks to develop a pilot training program and maintenance and repair capability in Korea for efficient operation of eGyro fleet.
The eGyro will leverage Mobius’ novel battery module architecture and low total cost of ownership providing power-as-a-service business model. “The high energy density, unmatched power boost, and outstanding thermal management of the Mobius battery modules support our efforts to produce an aircraft with best-in-class range and performance. We are excited to be the UAM launch platform for the Mobius battery module and service”, said Don Woodbury, Skyworks’ Co-Founder & Chief Technology Advisor.
Jongwon “JP” Park, Chief Strategy Officer and Co-Founder of Mobius said, “Mobius’ is building a global aviation battery alliance and our partnership with Skyworks to bring the eGyro to the Korean market marks an important milestone. Skyworks is the first of many customers who recognized the performance and safety of Mobius’ battery.”
About Mint Air
Mint Air is a startup company in stealth mode until now building an Advanced Air Mobility Service in South Korea. Mint Air’s approach is to facilitate an ecosystem of partners to accelerate the adoption of electric flight in Korea. A former global engineering part manufacturing company, Mint Air will take advantage of its global business experience and network to accelerate the development of the Urban Air Mobility ecosystem in Asia-Pacific markets. Beginning with air taxi operation, Mint Air aspires to become a global electric aircraft manufacturing company building electric aircraft supply chain, developing critical part manufacturing capability, and eventually assembling eGyro in Korea. For more information about the company, visit www.mintair.kr
About Mobius
Mobius.energy is developing safe, light, and energy-efficient novel battery module architecture. The module’s high discharge rate provides on-demand power boost needed during the take-off of electric aircraft at 7C which can last over 6 minutes. Its equally high charge rate enables fast charging in less than 10 minutes. Its light, simple, and compact design enables easy maintenance, on-site swapping, and cost-effective re-use and recycling. Mobius’ goal is to build battery subscription, maintenance, and salvage service including the second life repurpose and the end-of-life recycling of batteries to enable circular economy and thereby contribute to decarbonization of the aviation industry. For more information about the company, visit www.mobius.energy
About Skyworks Aeronautics
Skyworks Aeronautics is the world leader in the science and technology of gyronautics, focusing on the design and development of high-performance gyroplanes. Skyworks gyroplanes provide more affordable, safer, and higher performance alternatives for runway-independent aircraft.
Skyworks has more than 40 patents with several more underway, all obtained in an effort to radically change not only the way gyroplanes are perceived, but also the way they are utilized. From mass personnel transportation, agriculture, defense, and border protection to changing the economies of developing nations, Skyworks' goal is to change the nature of vertical flight. For more information about the company, its products, and individual members of the Skyworks team, visit www.skyworks-aero.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210624005323/en/
Contact information
Steve G. Stevanovich
steve@skyworks-aero.com
+1 312 809 1076
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indication. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors, BeOne Medicines, said: “HERIZON‑GEA‑01 has the potential to shift the treatment paradigm in this historically difficult-to-treat disease, with the TEVIMBRA-containing arm demonstrating an unprecedented 26-month survival benefit. The FDA’s Prior
European Commission (EC) Approves Henlius and Organon’s POHERDY ® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 12:30:00 EEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
CORRECTING and REPLACING Yoshihiro Shimamura, a Leading Investor in Japan’s Entertainment Industry, to Host Workshop at the 2026 Cannes Film Festival29.4.2026 11:49:00 EEST | Press release
Headline of release dated April 27, 2026 should read: Yoshihiro Shimamura, a Leading Investor in Japan’s Entertainment Industry, to Host Workshop at the 2026 Cannes Film Festival The updated release reads: YOSHIHIRO SHIMAMURA, A LEADING INVESTOR IN JAPAN’S ENTERTAINMENT INDUSTRY, TO HOST WORKSHOP AT THE 2026 CANNES FILM FESTIVAL Shimamura Yoshihiro Film Planning Inc. (Head Office: Osaka, Japan; CEO: Yoshihiro Shimamura), a company engaged in film production and investment, will host a workshop in France during this year’s Cannes Film Festival, as part of its commitment to further advancing the entertainment industry. The company invests in leading entertainment-related businesses in Japan and places strong emphasis on long-term value creation. It identifies the cultural and entertainment sectors as high-growth areas and is actively involved in international co-productions as a core part of its film production activities. As a recent investment, the company acquired 2,000,000 shares of
Andreas Goppelt Appointed Managing Director of OrphaCare29.4.2026 11:27:00 EEST | Press release
OrphaCare, a global specialist for the development and marketing of medical devices for drug delivery and part of the AOP Health Group, has appointed Andreas Goppelt as its new Managing Director, succeeding Georg Fischer. In this role, the seasoned medical device expert will focus on broadening the company’s strategic scope and driving its next phase of growth. OrphaCare plays a key role in supporting AOP Health’s integrated therapies approach, and the Group’s long-term expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429303533/en/ Portrait Andreas Goppelt, Managing Director OrphaCare (copyright: AOP Health/Studio Koekart) Andreas Goppelt brings more than 25 years of leadership experience across MedTech, biotechnology and the pharmaceutical industry. He has a proven track record of driving innovation, scaling global organizations, and delivering growth in highly regulated healthcare environments. In his new role,
The Jury Has Been Announced for the Third Edition of the Reply AI Film Festival, Dedicated to the Best Short Films Generated With Artificial Intelligence29.4.2026 11:00:00 EEST | Press release
Reply [EXM, STAR: REY], an international group specialized in creating new business models enabled by AI and long committed to guiding younger generations in exploring emerging technologies, presents the jury of the third edition of the Reply AI Film Festival, the international competition aimed at creatives, directors, and filmmakers who want to challenge themselves in producing short films created using Artificial Intelligence tools. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429288361/en/ “Imaginatio Nova” is the theme of the 2026 edition, an invitation to explore a new phase of imagination, where human creativity is renewed through technology. Leading the jury will be Gabriele Salvatores, Italian director and screenwriter known for films such as Nirvana, Siberian Education, and Napoli - New York, and Academy Award® winner for Best Foreign Language Film with Mediterraneo. Joining him on the panel for the third edit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom